Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “California”

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerRecruiting
NCT07480356Phase 3Updated Aug 21, 2026
Sponsor: Protara Therapeutics
Bladder (Urothelial, Transitional Cell) Cancer · Non-Muscle Invasive Bladder Carcinoma · Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
United States, Ukraine
Study of Bitopertin in Participants With EPP or XLP (APOLLO)Active Not Recruiting
NCT06910358Phase 3Updated Aug 21, 2026
Sponsor: Disc Medicine, Inc
Erythropoietic Protoporphyria (EPP) · X-Linked Protoporphyria (XLP)
United States, Australia, Belgium, Canada, France +7 more
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:Recruiting
NCT07186101Phase 2Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Ulcerative Colitis
United States, Austria, Brazil, Canada, China +12 more
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)Recruiting
NCT06863272Phase 1, Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Castration-Resistant Prostatic Cancer · Metastasis
United States, Argentina, Australia, Brazil, Canada +14 more
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruiting
NCT07195695Phase 3Updated Aug 21, 2026
Sponsor: Boehringer Ingelheim
Non-small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +23 more
A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain InjuryRecruiting
NCT07455136N/AUpdated Aug 21, 2026
Sponsor: Hoffmann-La Roche
Traumatic Brain Injury
United States
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeRecruiting
NCT07153471Phase 3Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Osteoarthritis
United States, Canada, China, Germany, India +3 more
Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care PathwaysEnrolling By Invitation
NCT07775976N/AUpdated Aug 21, 2026
Sponsor: Peerbridge Health, Inc
Cardiovascular Diseases · Cardiovascular Diseases Risk · Cardiac Conduction System Disease · Bundle/Fascicular Abnormalities
United States
Measurement and Determinants of Diet Quality in Older AdultsRecruiting
NCT07780708N/AUpdated Aug 21, 2026
Sponsor: University of California, Los Angeles
None Volunteer
United States
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerRecruiting
NCT06820463Phase 2Updated Aug 21, 2026
Sponsor: AbbVie
Metastatic Colorectal Cancer
United States, Australia, Austria, Brazil, Canada +9 more
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)Recruiting
NCT07466316Phase 3Updated Aug 21, 2026
Sponsor: Children's Oncology Group
Rhabdomyosarcoma
United States, Canada
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis PainRecruiting
NCT07641517Phase 2Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Osteoarthritis, Knee · Chronic Pain
United States, Puerto Rico
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)Recruiting
NCT06997497Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Colon Adenocarcinoma · Rectal Adenocarcinoma
United States, Argentina, Australia, Brazil, Canada +24 more
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruiting
NCT07562152Phase 3Updated Aug 21, 2026
Sponsor: Immuneering Corporation
Pancreatic Cancer · Pancreatic Cancer Metastatic · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma
United States, Australia
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerActive Not Recruiting
NCT04576091Phase 1Updated Aug 21, 2026
Sponsor: National Cancer Institute (NCI)
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma
United States
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain MetastasesRecruiting
NCT06764940Phase 2Updated Aug 21, 2026
Sponsor: Biostar Pharma, Inc.
HER2-negative Breast Cancer Patients With Brain Metastases
United States
Optimal Treatment for Recurrent Clostridium DifficileTerminated
NCT02667418Phase 4Updated Aug 21, 2026
Sponsor: VA Office of Research and Development
Clostridium · Difficile · Fidaxomicin · Vancomycin
United States, Puerto Rico
Adjuvant Steroid Outcomes in Idiopathic Subglottic StenosisRecruiting
NCT07228104Phase 3Updated Aug 21, 2026
Sponsor: Johns Hopkins University
Idiopathic Subglottic Stenosis
United States
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)Recruiting
NCT06717347Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Diffuse Large B-Cell Lymphoma
United States, Argentina, Australia, Belgium, Brazil +30 more
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)Recruiting
NCT07116967Phase 3Updated Aug 21, 2026
Sponsor: Bristol-Myers Squibb
Plaque Psoriasis
United States, Argentina, Australia, Belgium, Brazil +20 more
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialRecruiting
NCT07391774Phase 3Updated Aug 21, 2026
Sponsor: National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage IIIA Breast Cancer AJCC v8 · Anatomic Stage IIIC Breast Cancer AJCC v8 · Estrogen Receptor-Positive Breast Carcinoma
United States, Puerto Rico
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Recruiting
NCT06393374Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple-Negative Breast Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsRecruiting
NCT05797168Phase 1, Phase 2Updated Aug 21, 2026
Sponsor: AstraZeneca
Ovarian Cancer · Lung Adenocarcinoma · Endometrial Cancer · Lung Squamous Cell Carcinoma
United States, Australia, Canada, China, Germany +7 more
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabNot Yet Recruiting
NCT07261241Phase 2Updated Aug 21, 2026
Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Neuroblastoma
United States
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruiting
NCT06769698Phase 2Updated Aug 21, 2026
Sponsor: Regeneron Pharmaceuticals
Head and Neck Squamous Cell Carcinoma (HNSCC)
United States, Australia, France, Italy, Spain

Previous page Next page